FDAapproval65% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for GSK.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Immunotherapy
- Sub-indication
- General
Related signal: GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors